- Policy
- The National Assembly speeds up the telemedicine bill
- by Lee, Jeong-Hwan Nov 10, 2021 05:55am
- With the government declaring a phased COVID-19, the National Assembly's Health and Welfare Committee is speeding up its review of amendments to the medical law, which temporarily introduces non-face-to-face treatment. The Welfare Committee plans to propose two amendments to the medical law aimed at legislating telemedicine at the plenary ses
- Company
- Ono's BTK inhibitor Velexbru was approved for sale
- by Nov 10, 2021 05:55am
- Onopharm (CEO Choi Ho-jin) announced on the 9th that it has received approval from the MFDS to sell BTK inhibitor Velexbrew as a monotherapy for patients with B cell-induced PCNSL. The first BTK inhibitor has emerged as a PCNSL treatment that has not yet been established. The basis for approval is the results of phase 1/2 clinical trials (
- Company
- Non-reimbursed prescriptions for migraine drug Ajovy begin
- by Eo, Yun-Ho Nov 9, 2021 05:55am
- The new migraine drug ‘Ajovy’ is now being administered without reimbursement in Korea. According to industry sources, Teva-Handok Pharma’s Calcitonin gene-related peptide (CGRP) targeting migraine drug, Ajovy (fremanezumab), which was released in Korea on the 18th of last month, is now available for prescriptions at several medical in
- Company
- Will Ildong sell Nexium with annual sales of 50 billion won?
- by Kim, Jin-Gu Nov 9, 2021 05:54am
- Daewoong and AstraZeneca will terminate a joint sales contract for Nexium, a PPI-based gastroesophageal reflux disease treatment. The new joint sales partner of the large item, which generated about 50 billion won in sales last year, is said to be likely to be Ildong. According to the pharmaceutical industry on the 9th, Daewoong and Astra
- Policy
- Moderna vaccine produced by SB has been applied
- by Lee, Tak-Sun Nov 9, 2021 05:53am
- The MFDS announced on the 8th that Moderna Korea has applied for permission to manufacture and sell the COVID-19 vaccine SPIKEVAX produced by Samsung Biologics in Korea. The vaccine induces an immune response by injecting antigen genes from COVID-19 in the form of mRNA to produce antigen proteins in the body. The MFDS announced that it wil
- Policy
- LG Chem seeks approval for its ‘Zemiglo+SGLT-2i’ combo
- by Lee, Tak-Sun Nov 9, 2021 05:53am
- LG Chem has applied for the marketing authorization of a combination drug that combines the DPP-4 diabetes treatment ‘Zemiglo (gemigliptin)’ with an SGLT-2 class inhibitor to the Ministry of Food and Drug Safety. With the new application, whether Zemiglo, one of the most successful locally developed novel drugs, will continue on its su
- Policy
- Will a recombinant flu vaccine be released in Korea, too?
- by Lee, Tak-Sun Nov 9, 2021 05:53am
- A gene recombinant influenza vaccine is expected to be released in Korea. Currently, flu vaccines made by using eggs or culturing cells are also on sale in Korea. The MFDS approved a phase 3 clinical trial plan for Sanofi's RIV4 vaccine on the 2nd. RIV4 is an abbreviation for Quardrivalent Recombinant Influenza Vaccine, which, in direct trans
- Company
- It is expected that the SGLT-2 combination will be activated
- by Eo, Yun-Ho Nov 8, 2021 05:52am
- Expectations are also rising for revitalization of the combination drug market along with the expansion of combined benefits for the drug SGLT-inhibitors. According to related industries, pharmaceutical companies with SGLT-2 inhibitors and DPP-4 inhibitors, such as Beringer Ingelheim, AstraZeneca, and MSD, will go through the registration
- Policy
- "Reference pricing will activate sales of generic drugs"
- by Lee, Jeong-Hwan Nov 8, 2021 05:51am
- A pharmacist-politician Seo Young-Seok of the Democratic Party of Korea criticized the generic drug policy failure of the government, saying that Korea should also aggressively implement the ‘reference pricing system’ used in the US and Europe to break collusive ties between doctors and drug companies and lead the generic policy system on
- Policy
- Will RWD drive accessibility to ultra-high-priced drugs?
- by Kim, Jung-Ju Nov 8, 2021 05:51am
- Korea’s RSA system is moving to become more of a performance-based mechanism rather than a finance-based system. Performance-based RSA means that the system will be using real-world data (RWD) from clinical practice as real-world evidence (RWE). Ultra-high-priced drugs like Kymriah inj. (tisagenlecleucel) have had difficulties in reimb
